Commercializing Gene Chip Technology for Predicting In-Stent Restenosis Post-Acute Coronary Syndrome Surgery: A Focus on IGFBP-1

Tao Lyu
Chifeng College Affiliated Hospital, Chifeng, Inner Mongolia, 024000, China.

DOI:https://doi.org/10.5912/jcb2041

Abstract:

This study elucidates the role of Insulin-like Growth Factor Binding Protein-1 (IGFBP-1) in regulating smooth muscle cell function via the PI3K/AKT/mTOR pathway, revealing its potential to mitigate in-stent restenosis (ISR) following percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) patients. Conducted with 208 patients from the Affiliated Hospital of Chifeng College, the research involved comprehensive testing including blood routines, myocardial markers, inflammatory factors such as CRP and IL-6, lipid levels, electrocardiograms, and cardiac ultrasound. Serum levels of IGFBP-1 were specifically measured to assess their correlation with the risk of ISR post-PCI.Results indicate a significantly lower incidence of ISR in patients with higher serum IGFBP-1 levels, with a pivotal concentration threshold of 7.0 ?mol/L initiating a notable pro-proliferative effect on smooth muscle cells. The statistical analysis confirms that higher IGFBP-1 levels are positively correlated with reduced ISR rates (P=0.036<0.05). These findings suggest that IGFBP-1 could serve as a predictive biomarker for ISR, providing a valuable tool for improving the prognosis of ACS patients undergoing PCI. The study supports the commercialization of gene chip technology that includes IGFBP-1 detection, which could significantly enhance clinical outcomes by enabling early identification and targeted interventions for patients at risk of ISR.